Charité CBF, Rheumatology, Berlin, Germany.
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S128-31. Epub 2010 Oct 28.
The disease modifying antirheumatic drug (DMARD) methotrexate (MTX) is widely used and well accepted for the treatment of patients with rheumatoid arthritis (RA). In ankylosing spondylitis (AS), the use of MTX is not recommended for the axial manifestations and may have some efficacy in the peripheral involvement. For this disease there is a lack of clinical trials, and most of the trials did not show efficacy on the axial symptoms of the disease. Furthermore, there is no evidence that MTX increases the effects or prevents the side effects of TNF-blockers if given in combination. In this paper the available data of MTX in AS will be discussed.
疾病修饰抗风湿药物（DMARD）甲氨蝶呤（MTX）广泛用于治疗类风湿关节炎（RA）患者，且被广泛接受。在强直性脊柱炎（AS）中，不建议将 MTX 用于轴性表现，而在周围受累中可能具有一定疗效。对于这种疾病，缺乏临床试验，并且大多数试验并未显示出对疾病轴性症状的疗效。此外，如果联合使用，尚无证据表明 MTX 会增加 TNF 阻滞剂的效果或预防其副作用。本文将讨论 MTX 在 AS 中的现有数据。
